Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for rare diseases. Its primary product, VYKAT XR (diazoxide choline extended-release tablets), is an FDA-approved once-daily oral treatment for hyperphagia in patients aged 4 years and older with Prader-Willi syndrome, addressing a critical unmet need in this genetic disorder. The company targets rare genetic conditions characterized by complex, life-threatening symptoms, particularly in the metabolic and endocrine therapeutic areas. Soleno Therapeutics, Inc. operates in the pharmaceuticals industry, emphasizing small molecule modalities for orphan indications. With a commercial-stage pipeline, it serves patients, healthcare providers, and families affected by these underserved conditions through innovative therapies designed to improve quality of life. Founded in 1999 and headquartered in Redwood City, California, Soleno Therapeutics, Inc. plays a pivotal role in advancing treatments for rare diseases with significant medical gaps.